Affimed NV. Daily Stock Analysis

Daily Stock Analysis, AFMD, Affimed NV, priceseries

Affimed NV. Daily Stock Analysis
Stock Information
Open
4.10
Close
4.11
High
4.22
Low
4.07
Previous Close
4.09
Daily Price Gain
0.02
YTD High
5.76
YTD High Date
Jan 3, 2022
YTD Low
3.59
YTD Low Date
Jan 28, 2022
YTD Price Change
-1.54
YTD Gain
-27.26%
52 Week High
11.74
52 Week High Date
Apr 26, 2021
52 Week Low
3.59
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-1.01
52 Week Gain
-19.73%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 1. 2017
2.10
Mar 21. 2017
2.47
14 Trading Days
17.62%
Link
LONG
Jul 3. 2017
2.15
Jul 18. 2017
2.39
10 Trading Days
10.94%
Link
LONG
Feb 1. 2018
1.85
Feb 13. 2018
2.05
8 Trading Days
11.03%
Link
LONG
May 9. 2018
2.15
May 25. 2018
2.34
12 Trading Days
8.90%
Link
LONG
Oct 31. 2018
3.15
Nov 13. 2018
3.83
9 Trading Days
21.59%
Link
LONG
Sep 11. 2019
2.92
Sep 26. 2019
3.31
11 Trading Days
13.21%
Link
LONG
Dec 12. 2019
2.49
Dec 27. 2019
2.68
10 Trading Days
7.74%
Link
LONG
Apr 8. 2020
1.95
Apr 30. 2020
2.19
15 Trading Days
12.36%
Link
LONG
May 15. 2020
2.36
Jun 10. 2020
3.28
17 Trading Days
38.81%
Link
LONG
Jun 15. 2020
3.28
Jul 6. 2020
4.40
14 Trading Days
34.08%
Link
LONG
Nov 9. 2020
3.73
Dec 18. 2020
6.50
28 Trading Days
74.26%
Link
LONG
Mar 10. 2021
6.77
Mar 24. 2021
7.80
10 Trading Days
15.15%
Link
LONG
Apr 21. 2021
10.04
Apr 30. 2021
10.69
7 Trading Days
6.43%
Link
LONG
Aug 23. 2021
6.10
Sep 3. 2021
6.66
9 Trading Days
9.22%
Link
LONG
Oct 25. 2021
6.19
Nov 4. 2021
6.57
8 Trading Days
6.09%
Link
Company Information
Stock Symbol
AFMD
Exchange
NasdaqGM
Company URL
http://www.affimed.com
Company Phone
49-6221-65307
CEO
Adi Hoess
Headquarters
-
Business Address
IM NEUENHEIMER FELD 582, 69120, HEIDELBERG, GERMANY 000000
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001608390
About

Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. Affimed was founded in 2000 and is headquartered in Heidelberg, Germany.

Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Its AFM21 product also binds CD3, directing T-cells to destroy tumor cells that carry EGFRvIII. Affimed N.V. has license agreements with Amphivena Therapeutics, Inc. and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and clinical research collaboration with Merck & Co Inc. It also has a strategic clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate Affimed's TandAb technology in combination with MD Anderson's natural killer cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading